For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rivastigmine - Multiple sclerosis
PAD Profile : Rivastigmine - Multiple sclerosis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Fampridine
- Fingolimod
- Naltrexone hydrochloride
- Teriflunomide
- Modafinil
- Cladribine
- Peginterferon beta
- Memantine hydrochloride
- Donepezil hydrochloride
- Galantamine
Other Indications
Additional Documents
Committee Recommendations
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend AChE inhibitors* or memantine for people with cognitive impairment caused by multiple sclerosis, in line with NICE guideline (NG97)
* AChE inhibitors - donepezil, galantamine amd rivastigmine